Patented Hydrophilic Coating 8-63 Additive Compatible

Patented Hydrophilic Coating 8-63 Additive Compatible for drug delivery and other additives. This product has reduced slip, but more binder for a stronger film. The additive compatible coating is appropriate for radiopaques, bioactives, pigments, tracers, etc. Contact us at info@coatings2go.com for more information.

Kits are supplied as follows:

4oz kit comes with one (1) x 5g XLA and one (1) x 5g XLB

12oz kit comes with one (1) x 5g XLA and one (1) x 10g XLB

32oz kit comes with one (1) x 15g XLA and two (2) x 15g XLB

NOTE:

• During the winter months, all products will ship via overnight service because the coating cannot freeze
• International orders are subject to an additional $50 handling and processing fee and possible EEI filing (for orders over $2500) and bank wire fees. International orders must include carrier account information for shipping, duties, fees and taxes.
• If the time-of-sale shipping fee payment is less than the actual cost to ship (due to additional Duties and Taxes fees upon delivery), an invoice for the difference may be issued after your purchase.

The product is supplied as a kit with Crosslinkers A & B for improved strength and adhesion. 

Based on association forces between the hydrophilic and supporting polymers, or a patented interpenetrating network formed in-situ during drying, these urethane systems can reduce kinetic friction to below 0.1.

US Patent 6,238,799 Hydrophilic Coating 2001, US Patent 6,866,936 Hydrophilic Coating 2004, US Application 60-797,404 Hydrophilic Coating 2006, US Patent 9,080,061 Multiple Crosslink Functionalities 2015

Click here for Material Safety Data Sheet

Click here for a Study: Transgene Delivery for Plasmid DNA to Smooth Muscle Cells and Macrophages from a Biostable Polymer-Coated Stent

Click here for a Study: Covalent Heparin Research and Case Study

Click here for a study: Bacterin – Covalent Antibacterial Attachment – one step

Advantages:

• Therapeutic agents are released locally from devices to provide maximum benefit where the treatment is most needed.
• Release rate and time period are customizable to optimize the clinical benefit.
• Optimized, site-specific dosages are administered without adverse effects common to systemic treatments.

Therapies:

• Antithrombogenic
• Antimicrobial
• Analgesics
• Vitamin/antioxidative
• Antiproliferative
• Angiogenesis factors
• Antiangiogenesis factors

Your protein/gene therapy for:

• Cell growth regulation
• Immune response regulation
• Skin/ organ tissue
• Vascular/coronary
• Cancer treatments
• Bone/cartilage/dental
• Neural/ocular system
• Let your imagination find the limits.

Sustained Release/Drug Attachment Technology

Sustained drug attachment and release therapies provide a framework to release therapeutic agents over an extended time period from a medical device.

US Patent 6096726 Sustained release of bioactive materials 2000 US Patent 6,683,062 Multicomponent Complex for Use with a Substrate 2004 US Patent Pending Sustained release one-step coating

Patented systems use crosslinking agents to bind the supporting polymers to each other for better strength and resistance to solvents, sterilizing materials, heat and body fluids. Crosslinkers also bind to functional groups on the surface to improve adhesion. For drug delivery applications it is possible to bind and immobilize pharmaceutical agents to the surface allowing for sustained release, or surface immobilization.